ProteinSimple
Latest round
- Series F
Last raised
- May 2011
Total raised
- $85M
Investors
- 9
About ProteinSimple
Founded in 2004 and headquartered in Santa Clara, US, ProteinSimple develops instruments that cater to protein research. The company was acquired by Bio-Techne Corporation in June 2014 for USD 300 mn, marking a strategic pivot in its operational framework.ProteinSimple specializes in the development, manufacturing, and distribution of advanced analytical instruments and reagents tailored for protein research. The company's flagship products include the Simple Western, iCE, Ella, and Milo systems. These instruments are designed to facilitate high-throughput protein analysis, enabling researchers to obtain critical data on protein quantity, identity, expression, isoform variations, and purity within hours. For instance, Simple Western offers an automated platform that processes small sample volumes, providing rapid results essential for drug development and biomarker discovery. The iCE system is specifically engineered for intact protein characterization, while Ella provides a benchtop solution for automated ELISA applications.ProteinSimple generates revenue through a structured model involving direct sales and service agreements with B2B clients, particularly in the pharmaceutical and biotech sectors. The company offers its instruments and associated services as part of a comprehensive package, allowing customers to engage in both one-time purchases and ongoing service contracts. Clients typically initiate transactions by requesting quotes for specific instruments, including the Simple Western and Ella systems, which are then followed by purchase orders. Pricing structures for these high-value instruments reflect their specialized capabilities and the research needs of clients, although specific pricing details are proprietary.Following the acquisition by Bio-Techne Corporation, ProteinSimple aims to leverage additional resources to enhance its product offerings. The company is currently focused on developing new versions of their existing systems, with plans to launch upgraded models by mid-2025. Additionally, ProteinSimple is targeting expansion into the Asia-Pacific market, specifically Japan and South Korea, by 2026.
Who invested in ProteinSimple
9 investors across 5 rounds
See all investors in ProteinSimple
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ProteinSimple
Who invested in ProteinSimple?
ProteinSimple has 9 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ProteinSimple raised?
ProteinSimple has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did ProteinSimple last raise money?
ProteinSimple's most recent round on record is a Series F, in May 2011.
What does ProteinSimple do?
Founded in 2004 and headquartered in Santa Clara, US, ProteinSimple develops instruments that cater to protein research.
Where is ProteinSimple headquartered?
ProteinSimple is headquartered in Santa Clara, US.
Which VCs invest in companies like ProteinSimple?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biopolymers companies at ProteinSimple's stage. Their profiles are linked below.
VCs backing biopolymers startups at Series F
Raising like ProteinSimple? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.